Stockscreener 앱 받기
0.1423
7.11%
-0.0109
시장 영업 전:
.15
0.0077
+5.41%
전일 마감가:
$0.1532
열려 있는:
$0.158
하루 거래량:
597.47K
Relative Volume:
0.37
시가총액:
$2.06M
수익:
순이익/손실:
$-12.91M
주가수익비율:
-0.0015
EPS:
-94.5617
순현금흐름:
$-12.02M
1주 성능:
-24.65%
1개월 성능:
-48.68%
6개월 성능:
-97.68%
1년 성능:
-99.57%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.1416
$0.1839
52주 변동 폭
$0.1416
$34.70
Silexion Therapeutics Corp Stock (SLXN) Company Profile
명칭
Silexion Therapeutics Corp
전화
972-8-6286005
주소
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
0.1423 | 2.06M | 0 | -12.91M | -12.02M | -94.56 |
VRTX
Vertex Pharmaceuticals Inc
|
540.00 | 136.87B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
222.76 | 88.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
818.77 | 84.30B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
897.85 | 56.46B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.56 | 42.03B | 5.76B | 514.49M | 1.10B | 4.4813 |
Silexion Therapeutics Corp 주식(SLXN)의 최신 뉴스
Form DEF 14A SILEXION THERAPEUTICS CORP For: 12 October By Investing.com - Investing.com Nigeria
Form DEF 14A SILEXION THERAPEUTICS CORP For: 12 October By Investing.com - Investing.com UK
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewswire Inc.
Silexion cuts warrant price to raise $840K in cash infusion - Dealroom
Silexion Therapeutics Announces Warrant Inducement Financing Deal - The Globe and Mail
Silexion Therapeutics Announces Warrant Inducement Financing Deal - TipRanks
Form 8K Silexion Therapeutics Corp For: 29 September By Investing.com - Investing.com UK
A cash deal at Silexion (SLXN) comes with rights to buy up to 6.4 million more shares. - Stock Titan
Silexion raises $837,000 through warrant exercise at reduced price - Investing.com
Silexion raises $837,000 through warrant exercise at reduced price By Investing.com - Investing.com Canada
Silexion Therapeutics Announces Exercise of Warrants - GlobeNewswire
Silexion Therapeutics Corp. Announces Immediate Exercise of Series E Warrants and Issuance of New Warrants in $837,366 Financing - Quiver Quantitative
Form PRE 14A SILEXION THERAPEUTICS CORP For: 26 September By Investing.com - Investing.com Canada
Silexion Therapeutics Receives Nasdaq Bid Price Deficiency Notice - The Globe and Mail
Silexion Therapeutics Shareholders Reject Capital Structure Changes - The Globe and Mail
Form PRE 14A SILEXION THERAPEUTICS CORP For: 26 September By Investing.com - Investing.com UK
Silexion Therapeutics Notified of Nasdaq Bid Price Deficiency, Trading Continues Unaffected - Kalkine Media
Silexion Therapeutics Receives Nasdaq Bid Price Deficiency Notice - TipRanks
Why Is the Market Watching Silexion Therapeutics (SLXN)? - kalkinemedia.com
Biotech Pre-Market Movers: TNON, AEON Surge; COO, CDT Slide - RTTNews
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences - GlobeNewswire
After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN) - TipRanks
Silexion (SLXNW) Range: Finishes Nearly Flat at $0.01 in Latest Trading; Next Test - vinanet.vn
Silexion Therapeutics Receives Nasdaq Delisting Notice, Plans Appeal - TipRanks
Silexion Therapeutics Received Notice of Delisting - TradingView
Silexion Therapeutics Executes Reverse Share Split Amid Strain - The Globe and Mail
Silexion Therapeutics Closes Public Offering and Strengthens Equity - The Globe and Mail
Silexion Therapeutics (SLXN) seeks huge share boost and reverse split to stay on Nasdaq - Stock Titan
Silexion Q2 EPS $(5.17) misses $(2.12) estimate; loss widens - scanx.trade
Silexion Therapeutics Raises $35 Million in August Public Offering - Minichart
Silexion Therapeutics Corp 2Q 2026: Net loss $3.55M, EPS $(12.41) — 10-Q Summary - TradingView
Silexion Initiates Phase 2/3 Pancreatic Cancer Trial on July 29 - Minichart
Silexion Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts - Moomoo
Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts - Quiver Quantitative
Silexion Therapeutics reports Q2 2026: $3.6M Q2 net loss, $2.2M cash at June 30 - TradingView
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Press Release: Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
Silexion Completes 1-for-10 Reverse Share Split - Minichart
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com Nigeria
Silexion Therapeutics Executes Reverse Share Split Amid Strain - TipRanks
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com India
Silexion Therapeutics Closes Public Offering and Strengthens Equity - TipRanks
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com Canada
Silexion Therapeutics Corp (SLXN) investors report 0% holding but retain warrants - Stock Titan
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com UK
Silexion Therapeutics Raises $2.5 Million in Best-Efforts Equity Offering With H.C. Wainwright - TradingView
Silexion Therapeutics Corp SEC Filing (Aug 12, 2026) - Stock Titan
Silexion Therapeutics Corp (SLXN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.14%
자본화:
|
볼륨(24시간):